Enovis Corp (ENOV) PT Raised to $71 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ENOV Hot Sheet
Price: $24.42 +16.90%
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
(Updated - December 19, 2023 6:15 PM EST)
Canaccord Genuity analyst William J. Plovanic raised the price target on Enovis Corp (NYSE: ENOV) to $71.00 (from $65.00) while maintaining a Buy rating.
You May Also Be Interested In
- Annovis Bio launches public offering to fund Alzheimer's, Parkinson's trials
- CVS Health (CVS) PT Lowered to $103 at Jefferies
- Datadog (DDOG) PT Lowered to $245 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
